during the last months, we have again made significant progress in our product development.
In an update to AILANI, we recently introduced the first two “Personas” for users specializing either in Healthcare or Food and Nutrition. AILANI Personas efficiently put the information front and center that these different types of users focus on. NICARA is increasingly proving to be a valuable tool improve results from clinical studies of neuro-degenerative diseases. And our new Industrial Biotechnology Platform is convincing more and more companies and research institutes.
In addition to product development, we also became involved in further publicly funded research projects. With DARIO for digital diagnostic support in heart failure and PANORAMIX for quantifying the risk of arising from mixtures of chemical substances, we recently launched together with partners from academia and industry two important projects in research areas relevant to us.
Yesterday we went live with our new website. In connection with this, we will present our product range to you even better and keep you up to date on significant innovations and news. Just visit it at www.biomax.com.
Enjoy reading this newsletter and stay healthy.
Your team from Biomax Informatics
Our experts presented AILANI's semantic search capabilities to a wide audience at several scientific conferences. Our offering includes a personalized Cloud solution based on public content as well as an Enterprise solution for the integration of proprietary data. AILANI makes search simple and delivers answers regardless of the quality of the original search term. By profiting from the large number of open access semantic resources you can accelerate your innovation cycle and gain an edge over your competitors.
With currently two different Personas, users can choose between AILANI for Healthcare and AILANI for Food and Nutrition. Both solutions integrate different domain-specific public data and ontologies and therefore provide best key word results and AI-based answers even to questions in natural language.
A detailed overview of the entire product range can be found on our new website.
At the beginning of November, we launched two new research projects together with partners form academia and industry.
Under the name DARIO, Biomax is coordinating a research project on digital diagnostic support for heart failure together with partners from the Institute for Applied Medical Technology at RWTH Aachen University and the Clinic for Cardiology, Angiology and Internal Intensive Care Medicine at RWTH Aachen University Hospital. Funded by the German Federal Ministry of Education and Research, Biomax is investing over one million euros in the development of this clinical decision support system. Read more…
PANORAMIX is a four-year project led by the Technical University of Denmark, focusing on innovative ways for quantifying the risk associated with exposure to chemical mixtures, without animal testing. The project is supported by the European Commission through the Horizon Europe program with a € 4.4 M grant. Biomax will provide the Knowledge Management to the project, enabling the interoperability and integration of multiple existing toxicology databases as well as providing the user interface to the chemical-mixture risk prediction tool developed in the project. Read more…
On the 29th annual meeting of the European Charcot Foundation we presented our latest results from the Eurostars MS-CONNECT project together with partners from VU Medical Center Amsterdam and Universitätsspital Basel. The researchers were able to detect alterations in the individual connectome of multiple sclerosis patients compared to matched controls, which could support the monitoring and diagnosis of MS patients. Read more…
On November 30, 2021, we will host a free live online seminar about NICARA, titled “Increase the value of imaging biomarker studies in neurodegenerative disease clinical trials”. Dr. Markus Butz-Ostendorf will show you how to make most advanced neuroimaging processing pipelines available for your Alzheimer’s and neurodegeneration clinical trials. The webinar will be held in English and will last about half an hour followed by a Q&A session with all participants. Register here...
On December 2, 2021, as part of the NanoCommons project on a European nanoinformatics infrastructure, Dr. Dieter Maier will present a workshop on “Finding and accessing nanotoxicology data across multiple data sources with the NanoCommons Knowledge Base”, a BioXM driven part of the infrastructure. Register here...
Biomax Informatics AG Registered Office (Sitz der Gesellschaft): Planegg, Germany
Court of Registration (Registergericht): AG München, HRB 134442
CEO (Vorstandsvorsitzender): Dr. Klaus Heumann
Chairman of the Supervisory Board (Vorsitzender des Aufsichtsrats): Prof. Dr. Hans-Werner Mewes